

**AMENDMENTS TO THE CLAIMS**

Please amend claim 23, as shown below. A complete listing of the claims in this case, including their current status, is shown below.

**1-22. (Cancelled)**

23. **(Currently amended)** A method of inhibiting the trafficking of systemic memory T cells to a site of inflammation in a mammalian host, the method comprising:

administering an effective amount of an antagonist anti-CCR4 antibody in a dose effective to inhibit said trafficking of systemic memory T cells.

24. **(Previously presented)** The method of claim 23, wherein the site of inflammation is an endothelial cell.

25. **(Previously presented)** The method of claim 24, wherein the endothelial cell is activated.

26. **(Previously presented)** The method of claim 23, wherein the antibody inhibits the binding of CCR4 to TARC.

27. **(Previously presented)** The method of claim 23, wherein the antibody inhibits adhesion of the cells to cells at the site of inflammation.

28. **(Previously presented)** The method of claim 23, wherein the antibody inhibits chemotaxis of the cells.

**29. (Cancelled)**

30. **(Previously presented)** The method of claim 23, wherein the antibody is a monoclonal antibody.
31. **(Previously presented)** The method of claim 23, wherein the antibody is humanized.
32. **(Cancelled)**
33. **(Withdrawn)** The method of claim 23, wherein the site of inflammation is a site of psoriasis.
34. **(Withdrawn)** The method of claim 23, wherein the site of inflammation is a site of lichen planus.
35. **(Previously presented)** The method of claim 23, wherein the site of inflammation is a site of atopic dermatitis.
36. **(Withdrawn)** The method of claim 23, wherein the site of inflammation is a site of delayed hypersensitivity.
37. **(Withdrawn)** The method of claim 23, wherein the site of inflammation is a site of chronic inflammation.
38. **(Withdrawn)** The method of claim 23, wherein the site of inflammation is a site of an inflamed tonsil.